Clinical trial
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
NCT00367601 · Nasser Hanna, M.D., Other · Completed
Key facts
| NCT number | NCT00367601 |
|---|---|
| Title | Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Nasser Hanna, M.D., Other |
| Collaborators | Genentech, Inc. Industry Walther Cancer Institute Hoosier Cancer Research Network |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Bevacizumab |
| Enrollment | 25 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 23, 2006 |
| Last update posted | Feb 11, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: